Treating a pulmonary embolism means addressing a blood clot that is obstructing blood flow to the lungs. Catheter-based therapies have expanded physicians’ options, but there is still room to improve how clot-dissolving drugs are delivered and how clinicians assess a patient’s response during treatment.
Flow Medical is developing a catheter platform designed to bring those capabilities together.
Its investigational HELYX-PE System combines an expandable infusion scaffold, integrated angiography, and continuous pulmonary artery pressure monitoring. The platform is intended to improve drug distribution, streamline procedures, and give physicians real-time information to guide treatment decisions.
That approach comes from direct clinical experience. Flow was spun out of the University of Chicago and is led by CEO and co-founder Jennifer Fried alongside physician co-founders. Co-founder Jonathan Paul leads UChicago Medicine’s Pulmonary Embolism Response Team, a multidisciplinary program that evaluates approximately 500 patients annually. That experience provides a close view of where existing treatment workflows can improve.
Flow has closed $6M in financing, including participation from multiple strategic medical device investors. The funding will support first-in-human clinical evaluation, continued product development and manufacturing, and preparations for a U.S. pivotal study intended to support a future FDA submission. It will also fund the quality and regulatory work needed to advance the system.
This is an important transition from preclinical development toward evaluating the technology in patients. The system remains investigational and is not commercially available.
Proud to back Jennifer and the Flow Medical team as they work toward the next stage of development.
Read the full article in Today’s Medical Developments.
Join Jelly, Build with Everywhere’s private market intelligence platform!
Jelly is a startup discovery and research platform that brings together millions of data points on private companies, investors, funding activity, accelerator batches, and more.


